Immune checkpoint inhibitors (ICIs) are monoclonal antibodies that block co-inhibitory receptors on T cells or their ligands on tumor cells and antigen-presenting cells, releasing the brakes on the antitumor immune response. Understanding the distinct biology of CTLA-4 (cytotoxic T-lymphocyte antigen 4) versus the PD-1 (programmed death 1)/PD-L1 (programmed death ligand 1) axis is essential for predicting their clinical differences in toxicity, efficacy, and combination rationale.
CTLA-4 Biology and Ipilimumab. CTLA-4 is an inhibitory receptor expressed on activated T cells and constitutively on regulatory T cells (Tregs). During T-cell priming in lymph nodes, CTLA-4 competes with the co-stimulatory receptor CD28 (cluster of differentiation 28) for binding to B7 (B-lymphocyte antigen 7; CD80/CD86) ligands on antigen-presenting cells (APCs); because CTLA-4 has higher affinity for B7 than CD28, its engagement suppresses the co-stimulatory signal required for full T-cell activation and promotes Treg-mediated suppression.1 Ipilimumab is a fully human IgG1 antibody targeting CTLA-4 that blocks this inhibitory interaction, amplifying T-cell priming and depleting intratumoral Tregs via antibody-dependent cellular cytotoxicity (ADCC). Because CTLA-4 acts at the priming phase in lymph nodes rather than at the effector phase in tumor tissue, ipilimumab produces broad immune activation affecting many T-cell clones, explaining its higher and more diverse immune-related adverse event (irAE) rate compared to PD-1 (programmed death 1)/PD-L1 (programmed death ligand 1) inhibitors. Ipilimumab is approved for unresectable or metastatic melanoma (as monotherapy and in combination with nivolumab), adjuvant melanoma, renal cell carcinoma (RCC) in combination with nivolumab, colorectal cancer with mismatch repair deficiency (dMMR) in combination with nivolumab, hepatocellular carcinoma (HCC) in combination with nivolumab, and non-small cell lung cancer (NSCLC) in combination with nivolumab and chemotherapy.
PD-1 Biology and PD-1 Inhibitors. PD-1 is an inhibitory receptor expressed on effector T cells, particularly after antigen exposure in the tumor microenvironment (TME).2 PD-L1, the primary PD-1 ligand, is expressed on tumor cells, tumor-associated macrophages, and other stromal cells in the TME; its expression is often induced by interferon-gamma (IFN-gamma) released by tumor-infiltrating T cells, creating a feedback loop that limits immune clearance. PD-L2 (programmed death ligand 2), the second PD-1 ligand, is expressed predominantly on dendritic cells and macrophages. Because PD-1 acts at the effector phase in the tumor rather than the priming phase in lymph nodes, PD-1 blockade is more tumor-localized in its immune activation and produces a narrower irAE spectrum than CTLA-4 blockade. Approved PD-1 inhibitors are nivolumab (Bristol Myers Squibb; IgG4), pembrolizumab (Merck; IgG4), and cemiplimab (Regeneron/Sanofi; IgG4). Nivolumab and pembrolizumab are the most widely approved agents, with indications spanning melanoma, NSCLC, renal cell carcinoma, bladder cancer, head and neck squamous cell carcinoma (HNSCC), Hodgkin lymphoma, dMMR/MSI-H (microsatellite instability-high) solid tumors, gastric cancer, esophageal cancer, hepatocellular carcinoma, cervical cancer, colorectal cancer, and others.
PD-L1 Inhibitors: Atezolizumab, Durvalumab, and Avelumab. PD-L1 inhibitors block the PD-L1 ligand rather than the PD-1 receptor, with one important mechanistic distinction: PD-L1 blockade leaves PD-L2 (programmed death ligand 2)/PD-1 signaling intact, whereas PD-1 blockade disrupts signaling from both PD-L1 and PD-L2.2 Whether this distinction produces meaningful clinical differences in efficacy or toxicity remains debated. Atezolizumab is an engineered IgG1 antibody with Fc modifications that eliminate ADCC to reduce toxicity; approved for NSCLC (with chemotherapy or bevacizumab combinations), urothelial carcinoma, triple-negative breast cancer (TNBC [triple-negative breast cancer]; with nab-paclitaxel in PD-L1-positive tumors), and hepatocellular carcinoma (with bevacizumab). Durvalumab (IgG1) is approved for unresectable stage III NSCLC after chemoradiotherapy (PACIFIC [Pacific trial of durvalumab in stage III NSCLC after chemoradiotherapy]; consolidation durvalumab produced landmark improvement in PFS (progression-free survival) from 5.6 to 16.8 months)11 and for extensive-stage small cell lung cancer (ES-SCLC) with chemotherapy. Avelumab (IgG1) is approved for Merkel cell carcinoma and urothelial carcinoma maintenance after platinum-based chemotherapy.
ADME (Absorption, Distribution, Metabolism, Excretion) of Checkpoint Inhibitors. All clinically approved ICIs are IgG monoclonal antibodies sharing the pharmacokinetic principles described in Module 03: no CYP450 (cytochrome P450) metabolism, catabolized to amino acids, minimal renal excretion, half-lives of 14-27 days governed by FcRn recycling and target-mediated clearance.1 Pembrolizumab is dosed every 3 weeks (200 mg flat dose) or every 6 weeks (400 mg flat dose);13 the flat dosing strategy was validated by population PK (pharmacokinetic) modeling showing that body weight-based dosing provided no advantage in adults. Nivolumab is dosed every 2, 4, or 6 weeks depending on indication and combination. Ipilimumab is dosed every 3 weeks for four doses in the standard regimen; a lower-dose (1 mg/kg every 6 weeks) regimen is used in combination with nivolumab for NSCLC to reduce irAE burden while preserving efficacy. There are no hepatic or renal dose adjustments for checkpoint inhibitors; however, active autoimmune disease requiring systemic immunosuppression, prior organ transplant, and active infection with hepatitis B or C are relative or absolute contraindications requiring individual benefit-risk assessment.
Combination Checkpoint Inhibition: Rationale and Toxicity. The combination of nivolumab plus ipilimumab (dual checkpoint blockade targeting both PD-1 and CTLA-4) produces superior response rates and survival compared to either agent alone in melanoma (CheckMate 067 trial), RCC (CheckMate 214 trial), NSCLC (CheckMate 227 trial), and HCC, at the cost of substantially higher grade 3-4 irAE rates (59% for combination vs. 21% for nivolumab monotherapy in melanoma).1
The mechanistic synergy reflects complementary immune activation: CTLA-4 blockade amplifies the breadth of primed T-cell clones in lymph nodes, while PD-1 blockade restores effector function to exhausted tumor-infiltrating T cells. The combination is therefore more immunogenic at every step of the cancer-immunity cycle, producing deeper responses but also broader immune-related toxicity, particularly high-grade colitis, hepatitis, and endocrinopathies.
CTLA-4: ipilimumab (Yervoy; fully human IgG1). PD-1: nivolumab (Opdivo; IgG4), pembrolizumab (Keytruda; IgG4), cemiplimab (Libtayo; IgG4). PD-L1: atezolizumab (Tecentriq; engineered IgG1, no ADCC), durvalumab (Imfinzi; IgG1), avelumab (Bavencio; IgG1, retains ADCC). Key difference: CTLA-4 inhibitors act at T-cell priming in lymph nodes; PD-1/PD-L1 inhibitors act at effector phase in the tumor microenvironment. This distinction drives the broader irAE spectrum of ipilimumab versus PD-1/PD-L1 agents.
Immune-related adverse events (irAEs) are the defining toxicity class of checkpoint inhibitors, arising when released T-cell activity damages normal tissues. irAEs can affect virtually any organ system; the most clinically consequential involve the gastrointestinal tract, liver, lungs, endocrine glands, and skin. Prompt recognition and early initiation of immunosuppression are the cornerstones of management; delayed treatment substantially increases morbidity and mortality from severe irAEs.
General irAE Management Principles. irAE (immune-related adverse event) severity is graded using NCI (National Cancer Institute) CTCAE (National Cancer Institute Common Terminology Criteria for Adverse Events) criteria. The general management algorithm is: grade 1 (mild, no functional limitation) — continue ICI (immune checkpoint inhibitor) with close monitoring; grade 2 (moderate, limiting instrumental ADL [activities of daily living]) — hold ICI; initiate prednisone 1 mg/kg/day orally for most organ sites; grade 3 (severe, limiting self-care ADL) — permanently discontinue or hold ICI depending on organ and clinical context; initiate intravenous methylprednisolone 1-2 mg/kg/day; grade 4 (life-threatening) — permanently discontinue ICI; initiate IV methylprednisolone 1-2 mg/kg/day and escalate to infliximab or other steroid-sparing agents if no improvement within 3-5 days.3 Steroid tapering should be slow (over at least 4-6 weeks) after symptom resolution; premature taper causes irAE flares. ICIs should not be rechallenged after grade 4 irAEs or grade 3 irAEs involving the heart (myocarditis), nervous system (Guillain-Barre syndrome), or eye (uveitis with vision loss).
Immune-Related Colitis. Diarrhea and colitis are the most common gastrointestinal irAEs; they occur most frequently with CTLA-4 (cytotoxic T-lymphocyte antigen 4) inhibitors (approximately 30-40% any grade; 10-15% grade 3-4 with ipilimumab monotherapy) and less frequently with PD-1 (programmed death 1)/PD-L1 (programmed death ligand 1) inhibitors (approximately 10-15% any grade).3 Colitis presents as watery diarrhea (grade by number of stools above baseline per day: grade 1 = fewer than 4 extra stools/day; grade 2 = 4-6 extra stools/day with abdominal pain; grade 3 = 7 or more extra stools/day or hospitalization; grade 4 = life-threatening complications including perforation). Evaluation includes stool culture and Clostridium difficile testing to exclude infectious colitis; flexible sigmoidoscopy or colonoscopy is performed for grade 3-4 or refractory grade 2 colitis, showing diffuse mucosal edema, erythema, and ulceration histologically resembling inflammatory bowel disease. Grade 2 colitis: hold ICI; prednisone 1 mg/kg/day with taper over 4-8 weeks.
Grade 3-4 colitis: IV methylprednisolone 1-2 mg/kg/day; infliximab 5 mg/kg IV if no improvement in 3-5 days; infliximab does not impair ICI antitumor efficacy in retrospective analyses.
Immune-Related Hepatitis. ICI-associated hepatitis occurs in approximately 5-10% of patients on PD-1 (programmed death 1)/PD-L1 (programmed death ligand 1) inhibitors and 5-10% on ipilimumab monotherapy, rising to approximately 25-30% with nivolumab-ipilimumab combination.3 It presents as asymptomatic LFT (liver function test) elevation (ALT [alanine aminotransferase] or AST [aspartate aminotransferase]) discovered on routine monitoring; LFTs should be checked before each infusion. Grade 1 hepatitis (ALT [alanine aminotransferase]/AST [aspartate aminotransferase] less than 3 times ULN [upper limit of normal]): continue ICI with weekly monitoring. Grade 2 (ALT/AST 3-5 times ULN): hold ICI; prednisone 0.5-1 mg/kg/day; rechallenge once resolved to grade 1 or lower. Grade 3 (ALT/AST 5-20 times ULN): hold ICI (likely permanently); IV methylprednisolone 1-2 mg/kg/day; add mycophenolate mofetil 500-1000 mg twice daily if no improvement after 3 days (infliximab is avoided in hepatitis because it is itself hepatotoxic). Grade 4 (ALT/AST more than 20 times ULN): permanently discontinue ICI; IV methylprednisolone escalation; consider gastroenterology and hepatology consultation. Liver biopsy shows a pan-lobular hepatitis pattern with cytotoxic T-cell (cluster of differentiation 8-positive [CD8+]) infiltration, distinguishing immune-related from drug-induced liver injury.
Immune-Related Pneumonitis. ICI-associated pneumonitis occurs in approximately 3-5% of patients on PD-1 (programmed death 1) monotherapy, 7-10% on combination nivolumab-ipilimumab, and is more common in patients with NSCLC (lung cancer itself predisposes to pulmonary irAEs).3 Presentation ranges from asymptomatic bilateral ground-glass opacities on CT (computed tomography) to severe dyspnea and respiratory failure. Grade 1: hold ICI; CT every 3 weeks; resume if stable after 4-6 weeks. Grade 2: hold ICI; prednisone 1-2 mg/kg/day; bronchoscopy with BAL (bronchoalveolar lavage) to exclude infectious pneumonia; resume only if complete resolution. Grade 3-4: permanently discontinue ICI; IV methylprednisolone 1-2 mg/kg/day; add infliximab, mycophenolate mofetil, or IVIG (intravenous immunoglobulin) for steroid-refractory cases. Pneumonitis is the most common cause of ICI-related death; grade 5 (fatal) pneumonitis occurs in approximately 0.2-1% of patients. PJP (Pneumocystis jirovecii pneumonia) prophylaxis is recommended when prednisone doses exceed 20 mg/day for more than 4 weeks.
Immune-Related Endocrinopathies. Endocrine irAEs are unique in their management: unlike colitis, hepatitis, and pneumonitis, most endocrine irAEs are permanent (the gland is destroyed and cannot regenerate), and immunosuppression with steroids does not restore endocrine function but may be used to manage the acute inflammatory phase.4 The main endocrinopathies are: (1) thyroid disorders — hypothyroidism (most common endocrine irAE; approximately 8-10% on PD-1 monotherapy, higher with combination); hyperthyroidism/thyroiditis (approximately 3-5%); managed with levothyroxine (hypothyroidism) or beta-blockers and methimazole (hyperthyroidism); ICI continued in most cases;
Hypophysitis, Adrenal Insufficiency, and Type 1 Diabetes. Hypophysitis (pituitary gland inflammation; approximately 8-17% on ipilimumab, rare with PD-1/PD-L1 monotherapy) — presents as headache, fatigue, and visual field defects from pituitary mass; central hypothyroidism, central adrenal insufficiency, and hypogonadotropic hypogonadism from compression and destruction of pituitary trophic cells; MRI (magnetic resonance imaging) shows enlarged pituitary with homogeneous gadolinium enhancement; treated with high-dose corticosteroids acutely (to reduce inflammation and preserve pituitary function) followed by lifelong hormone replacement; ICI continued after stabilization;
Adrenal insufficiency (primary or secondary from hypophysitis) — presents as fatigue, hypotension, hyponatremia, hyperkalemia; cortisol and ACTH (adrenocorticotropic hormone) levels must be obtained before empiric steroid treatment obscures the diagnosis; treated with hydrocortisone replacement (15-25 mg/day in divided doses); ICI held acutely for adrenal crisis, continued after stabilization; (4) type 1 diabetes mellitus — rare but dramatic; fulminant insulin-dependent diabetes with DKA (diabetic ketoacidosis) presentation occurring within weeks of ICI initiation; managed with insulin replacement; ICI continued.
Infliximab (anti-TNF monoclonal antibody) is the preferred steroid-sparing agent for steroid-refractory grade 3-4 colitis: high efficacy, rapid onset (within 1-2 infusions), and does not worsen ICI antitumor activity. Infliximab is contraindicated for immune-related hepatitis (hepatotoxic risk). Mycophenolate mofetil (inhibits inosine monophosphate dehydrogenase, blocking lymphocyte proliferation) is preferred for steroid-refractory hepatitis. For pneumonitis and other organ-specific irAEs, mycophenolate mofetil, IVIG, or cyclophosphamide may be used depending on clinical severity and organ involved. Rituximab has been used for refractory neurotoxic irAEs. Tacrolimus or cyclosporine for refractory colitis or hepatitis in severe cases.
Identifying which patients will respond to checkpoint inhibition remains one of the central challenges of precision oncology. Three companion diagnostic biomarkers are clinically validated: PD-L1 (programmed death ligand 1) expression (measured as TPS [tumor proportion score] or CPS [combined positive score]), tumor mutational burden (TMB), and mismatch repair deficiency (dMMR)/microsatellite instability-high (MSI-H) status. Understanding the biologic rationale, assay methodology, and clinical utility of each is essential for appropriate patient selection.
PD-L1 Expression: TPS and CPS Scoring. PD-L1 is quantified on tumor biopsies by IHC (immunohistochemistry) using validated companion diagnostic assays; the scoring methodology differs by tumor type and therapeutic agent.5 TPS (tumor proportion score) counts PD-L1 staining on tumor cells only, expressed as a percentage of total tumor cells; it is used for NSCLC (pembrolizumab as monotherapy requires TPS of 50% or higher for first-line therapy without chemotherapy; TPS 1-49% requires chemotherapy combination). CPS (combined positive score) counts PD-L1-positive tumor cells, lymphocytes, and macrophages relative to total tumor cells, multiplied by 100; it is used for gastric cancer, esophageal cancer, HNSCC (head and neck squamous cell carcinoma), cervical cancer, and urothelial carcinoma (pembrolizumab approved at CPS [combined positive score] of 10 or higher in these tumors). The specific companion diagnostic assay (22C3, 28-8, SP263, SP142, or 73-10) must match the drug and indication; assays are not interchangeable across agents. PD-L1 expression is an imperfect predictive biomarker: approximately 20-30% of PD-L1-low tumors respond to ICI (immune checkpoint inhibitor) therapy, and 20-30% of PD-L1-high tumors are primary refractory, reflecting the fact that PD-L1 is a dynamic, inducible marker influenced by sampling site, heterogeneity, and prior treatment.
Tumor Mutational Burden. TMB (tumor mutational burden) quantifies the total number of somatic mutations per megabase of coding genome, measured by comprehensive genomic sequencing panels (e.g., Foundation Medicine FoundationOne CDx).5 The rationale is that tumors with high mutational burden generate more neoantigens (novel peptides presented by MHC [major histocompatibility complex] molecules to T cells), making them more immunogenic and more susceptible to checkpoint-mediated T-cell killing. The FDA (Food and Drug Administration) approved pembrolizumab for TMB-high (10 or more mutations per megabase) solid tumors regardless of histology (tumor-agnostic approval), though the predictive value of TMB is stronger in some tumor types (NSCLC, melanoma, bladder cancer) than others (colorectal cancer, breast cancer). TMB-high and MSI-H overlap substantially in colorectal cancer because dMMR produces hypermutation, but in other tumor types they identify largely distinct patient populations. TMB is complementary to PD-L1 and MSI-H testing; combining biomarkers improves predictive accuracy more than any single biomarker alone.
MSI-H and dMMR: Tumor-Agnostic Biomarkers. The MMR (mismatch repair) system corrects DNA (deoxyribonucleic acid) replication errors; deficiency in MMR proteins (MLH1, MSH2, MSH6, PMS2) allows microsatellite instability to accumulate throughout the genome.6 dMMR can be detected by IHC for loss of MMR protein expression; MSI-H can be detected by PCR (polymerase chain reaction) fragment analysis at standard microsatellite loci or by NGS (next-generation sequencing). dMMR/MSI-H tumors have markedly elevated mutational burden (typically more than 100 mutations per megabase in colorectal cancer), generating abundant neoantigens and robust tumor-infiltrating lymphocyte infiltration. Pembrolizumab was the first tumor-agnostic ICI approval (approved for any dMMR/MSI-H solid tumor after prior therapy, regardless of histology), followed by nivolumab and nivolumab-ipilimumab for dMMR/MSI-H colorectal cancer specifically. In Lynch syndrome (germline dMMR), colorectal, endometrial, gastric, and other cancers frequently exhibit MSI-H and are particularly ICI-responsive. Sporadic dMMR in colorectal cancer (typically caused by MLH1 promoter hypermethylation) also predicts ICI response but is additionally associated with BRAF (v-raf murine sarcoma viral oncogene homolog B) V600E (valine-to-glutamate at codon 600) mutation, which does not diminish ICI efficacy.
Primary and Acquired Resistance to Checkpoint Inhibitors. Despite robust biomarker selection, approximately 30-50% of patients with nominally favorable biomarkers exhibit primary resistance to ICI therapy, and most initially responding patients develop acquired resistance over 12-24 months.5 Tumor-intrinsic resistance mechanisms include: loss of antigen presentation (beta-2 microglobulin mutation or MHC-I [major histocompatibility complex class I] loss); oncogenic pathway activation that suppresses immunogenicity (WNT [wingless-related integration site]/beta-catenin signaling, STK11/LKB1 [serine-threonine kinase 11/liver kinase B1] mutations in NSCLC suppressing STING [stimulator of interferon genes] pathway); activation of alternative checkpoint pathways (LAG-3 [lymphocyte activation gene 3], TIM-3 [T-cell immunoglobulin and mucin domain 3], TIGIT [T-cell immunoreceptor with Ig and ITIM domain]). Tumor-extrinsic mechanisms include: immunosuppressive TME (tumor microenvironment) driven by Tregs, MDSCs (myeloid-derived suppressor cells), and M2 (alternatively activated, immunosuppressive) macrophages; TGF-beta (transforming growth factor beta) secretion promoting immune exclusion; metabolic competition (IDO [indoleamine 2,3-dioxygenase] pathway tryptophan depletion; adenosine signaling). These resistance mechanisms define the targets of next-generation combination strategies pairing ICIs with LAG-3 inhibitors (relatlimab, approved with nivolumab for melanoma), TIGIT inhibitors, IDO inhibitors, TGF-beta inhibitors, and adenosine pathway agents.
Universal testing: dMMR/MSI-H testing is recommended for all patients with solid tumors given the tumor-agnostic pembrolizumab approval; colorectal and endometrial cancers have the highest prevalence. PD-L1 (TPS or CPS per tumor type and agent) and TMB testing should be performed as indicated by tumor histology and treatment line. Lynch syndrome germline testing should follow universal tumor MMR screening. Testing should be on the most recent biopsy when possible, as expression levels change with prior therapy. Plasma ctDNA (circulating tumor DNA) assays are increasingly used for TMB and MSI assessment when tissue is insufficient.
Hormonal therapy remains the backbone of treatment for hormone receptor-positive prostate and breast cancers, and its pharmacology spans four decades of clinical development from LHRH (luteinizing hormone-releasing hormone) analogs to next-generation androgen receptor (AR) inhibitors and selective estrogen receptor degraders (SERDs). Clinicians in all specialties encounter patients on these agents and must manage their toxicity profiles, drug interactions, and monitoring requirements.
GnRH Agonists and Antagonists in Prostate Cancer. Medical castration suppressing testosterone to below 50 ng/dL is the foundation of androgen deprivation therapy (ADT) for advanced prostate cancer.7 GnRH agonists (leuprolide, goserelin, triptorelin) initially cause a testosterone surge due to receptor stimulation, before inducing receptor downregulation and castrate levels after 2-4 weeks; this initial flare, which can exacerbate bone pain, urinary obstruction, or spinal cord compression in patients with bulky metastatic disease, is prevented by concurrent antiandrogen (bicalutamide) administration for the first 4 weeks. GnRH antagonists (degarelix; relugolix, the only oral GnRH antagonist) directly block pituitary GnRH receptors without initial stimulation, producing rapid castration within 3 days without testosterone flare; relugolix is particularly advantageous in patients with cardiac disease because it appears to have lower cardiovascular event rates than GnRH agonists (though GnRH agonists themselves are associated with increased cardiovascular risk including MI [myocardial infarction], stroke, and sudden cardiac death, attributed to metabolic effects of castration including dyslipidemia and insulin resistance).
ADT class toxicities include hot flashes, osteoporosis (DEXA [dual-energy X-ray absorptiometry] scan monitoring and bisphosphonate/denosumab prophylaxis recommended for long-term ADT), muscle loss, cognitive effects, and metabolic syndrome.
Next-Generation AR Inhibitors: Enzalutamide, Apalutamide, and Darolutamide. Enzalutamide is an oral, non-steroidal AR inhibitor that blocks testosterone and dihydrotestosterone (DHT) binding to AR, inhibits AR nuclear translocation, and prevents AR from binding DNA (deoxyribonucleic acid) or recruiting co-activators, providing more complete AR pathway suppression than older antiandrogens (bicalutamide, flutamide) that act only at the ligand-binding step.7 Enzalutamide is metabolized primarily by CYP3A4 (cytochrome P450 3A4) and CYP2C8 (cytochrome P450 2C8), and is a strong inducer of CYP3A4, CYP2C9 (cytochrome P450 2C9), and CYP2C19 (cytochrome P450 2C19) at therapeutic doses; this induction substantially reduces plasma concentrations of co-administered drugs metabolized by these enzymes, including warfarin (INR [international normalized ratio] monitoring essential), apixaban, rivaroxaban, and multiple oncology agents. Enzalutamide approval spans castration-sensitive high-risk prostate cancer (ARCHES [androgen receptor pathway inhibition with enzalutamide] trial, ENZAMET trial), castration-resistant prostate cancer (CRPC) with metastases, and non-metastatic CRPC with rapid PSA (prostate-specific antigen) doubling time. CNS (central nervous system) toxicities include fatigue (approximately 30%), dizziness, and rare but serious seizures (approximately 0.1-0.9%); enzalutamide lowers the seizure threshold by GABA-A (gamma-aminobutyric acid type A) receptor antagonism and is contraindicated in patients with prior seizure history.
Apalutamide is structurally similar to enzalutamide with a similar mechanism and CYP (cytochrome P450) induction profile; it carries a risk of skin rash (approximately 24%) and hypothyroidism (approximately 8%). Darolutamide has a structurally distinct AR-binding domain that reduces CNS penetration; it does not cause seizures at therapeutic doses and has a more favorable CYP interaction profile (not a strong CYP inducer), making it preferred in patients with seizure history or extensive polypharmacy.
Abiraterone: CYP17A1 (Cytochrome P450 17A1) Inhibitor. Abiraterone acetate is an oral prodrug converted to abiraterone, a potent, irreversible inhibitor of CYP17A1 (17-alpha-hydroxylase/17,20-lyase), the enzyme responsible for androgen synthesis in the adrenal glands and intratumoral tissues as well as in the testes.7 By blocking CYP17A1, abiraterone suppresses androgen production from all sources (adrenal and intratumoral), achieving more complete androgen deprivation than castration alone. A mandatory co-administration requirement is prednisone 5 mg twice daily (or prednisolone 5 mg twice daily) throughout abiraterone therapy: CYP17A1 inhibition in the adrenal cortex blocks cortisol synthesis upstream of the enzyme, causing compensatory ACTH (adrenocorticotropic hormone) elevation that drives accumulation of mineralocorticoid precursors (11-deoxycorticosterone, corticosterone) upstream of CYP17A1; these mineralocorticoids cause hypertension, hypokalemia, and fluid retention. Prednisone suppresses ACTH and replaces cortisol. Monitoring requirements include blood pressure, serum potassium, and LFTs before each cycle. Abiraterone must be taken on an empty stomach (a high-fat meal increases abiraterone AUC (area under the concentration-time curve) by approximately 5-fold, causing unpredictable toxicity); a newer formulation, abiraterone acetate (Yonsa) with nanocrystal technology, can be taken with a low-fat meal. CYP2D6 (cytochrome P450 2D6) inhibition by abiraterone increases dextromethorphan exposure; this is not typically clinically significant but is documented.
Hormonal Therapy in Breast Cancer: Tamoxifen, Aromatase Inhibitors, and Fulvestrant. Tamoxifen is a selective estrogen receptor modulator (SERM) that binds the estrogen receptor (ER) as a competitive antagonist in breast tissue while acting as a partial agonist in endometrium and bone; it is used as adjuvant therapy for 5-10 years in ER-positive early breast cancer and in premenopausal metastatic ER-positive disease.8 Tamoxifen is a prodrug metabolized to the active metabolite endoxifen by CYP2D6; patients with CYP2D6 poor metabolizer genotype (approximately 7% of Europeans) generate substantially less endoxifen and may derive less benefit from tamoxifen. Strong CYP2D6 inhibitors (fluoxetine, paroxetine) markedly reduce endoxifen levels and should be avoided; venlafaxine is preferred for hot flash management. Tamoxifen increases endometrial cancer risk approximately 2-fold and VTE (venous thromboembolism) risk; annual gynecological evaluation is recommended.
Aromatase Inhibitors, Fulvestrant, and Elacestrant. Aromatase inhibitors (AIs; letrozole, anastrozole, exemestane) suppress extragonadal estrogen synthesis by blocking aromatase (CYP19A1), which converts androgens to estrogens in adipose, adrenal, and breast tissue; AIs are only effective in postmenopausal women (or ovarian-suppressed premenopausal women) where extragonadal estrogen is the dominant source. AIs produce superior DFS (disease-free survival) compared to tamoxifen in postmenopausal women in the adjuvant setting; primary toxicities are musculoskeletal symptoms (approximately 40%) and accelerated bone loss requiring DEXA (dual-energy X-ray absorptiometry) monitoring and bisphosphonate/denosumab.
Fulvestrant is a pure ER antagonist and degrader (SERD [selective estrogen receptor degrader]) with no agonist activity; it is administered as a monthly intramuscular injection and is used in ER-positive metastatic breast cancer after AI (aromatase inhibitor) failure, including in combination with CDK4/6 (cyclin-dependent kinase 4/6) inhibitors. Elacestrant is an oral SERD approved for ESR1 (estrogen receptor 1 gene)-mutant metastatic breast cancer after endocrine therapy; ESR1 mutations are a common mechanism of acquired resistance to AIs and are detected by ctDNA (circulating tumor DNA) liquid biopsy.
Tamoxifen requires CYP2D6-mediated conversion to endoxifen for antitumor activity. Paroxetine and fluoxetine are potent CYP2D6 inhibitors that reduce endoxifen levels by approximately 60-70%, potentially diminishing tamoxifen efficacy. When hot flash management is required in a tamoxifen-treated patient, prescribe venlafaxine, desvenlafaxine, gabapentin, or clonidine rather than paroxetine or fluoxetine. Dual CYP2D6 inhibition (drug plus genotype) produces phenocopying of poor metabolizer status; CYP2D6 genotyping before tamoxifen initiation is increasingly standard practice in some institutions. Codeine and tramadol are also CYP2D6 substrates; reduced analgesic efficacy may occur in poor metabolizers.
CAR-T (chimeric antigen receptor T-cell) therapy represents a paradigm shift in cellular immunotherapy, engineering a patient's own T cells to recognize and kill tumor cells expressing a specific surface antigen. Neuroendocrine tumor (NET) pharmacology, spanning somatostatin analogs and targeted agents, addresses a distinct but clinically important cancer subtype managed by the same oncologists who prescribe ICIs and hormonal agents.
CAR-T Cell Therapy: Manufacturing and Administration. CAR-T cell manufacturing involves leukapheresis of the patient's T cells, ex vivo genetic engineering to introduce a chimeric antigen receptor (a fusion of a single-chain variable fragment [scFv] antibody targeting a tumor antigen with intracellular T-cell signaling domains CD3 (cluster of differentiation 3)-zeta and co-stimulatory domains CD28 (cluster of differentiation 28) or 4-1BB), expansion of the engineered cells in culture, and cryopreservation for shipping back to the treatment center.9 The manufacturing process takes 2-6 weeks; bridging therapy may control disease during this window.
Before CAR-T infusion, patients receive a lymphodepleting conditioning regimen (typically fludarabine 25-30 mg/m2/day plus cyclophosphamide 250-500 mg/m2/day for 3 days), which depletes competing endogenous lymphocytes and creates cytokine space (particularly IL-7 [interleukin-7] and IL-15 [interleukin-15]) that supports CAR-T expansion and persistence. FDA-approved CAR-T products include: tisagenlecleucel (tisa-cel; anti-CD19, 4-1BB co-stimulatory domain) for relapsed/refractory B-cell ALL (acute lymphoblastic leukemia) in patients up to 25 years old and DLBCL (diffuse large B-cell lymphoma); axicabtagene ciloleucel (axi-cel; anti-CD19, CD28 co-stimulatory domain) for DLBCL, follicular lymphoma, and primary mediastinal B-cell lymphoma12; lisocabtagene maraleucel (liso-cel; anti-CD19, 4-1BB) for DLBCL and CLL (chronic lymphocytic leukemia); and idecabtagene vicleucel (ide-cel; anti-BCMA [B-cell maturation antigen]) and ciltacabtagene autoleucel (cilta-cel; anti-BCMA) for relapsed/refractory multiple myeloma. All CAR-T products are dispensed and administered under REMS (risk evaluation and mitigation strategy) programs given the risk of life-threatening toxicity.
Cytokine Release Syndrome (CRS). CRS is the most common serious toxicity of CAR-T therapy, occurring in 70-90% of patients (any grade) and grade 3 or higher in approximately 20-40%.9 CRS results from massive cytokine release (IL-6 [interleukin-6], IFN-gamma, IL-10, IL-2) as CAR-T cells recognize and lyse tumor cells, recruiting macrophages and other immune cells in a self-amplifying inflammatory cascade. Onset is typically within 1-14 days of infusion (earlier with CD28 vs. 4-1BB constructs). ASTC (American Society for Transplantation and Cellular Therapy) grading: grade 1, fever 38 degrees Celsius or higher, no hypotension or hypoxia; grade 2, fever with hypotension responsive to fluids and/or hypoxia requiring supplemental oxygen less than 6 L/min; grade 3, hypotension requiring vasopressors, hypoxia requiring high-flow oxygen; grade 4, life-threatening requiring mechanical ventilation or ECMO (extracorporeal membrane oxygenation). Biomarkers of severe CRS include markedly elevated ferritin (more than 10,000 ng/mL), CRP (C-reactive protein), IL-6, and LFTs. Grade 1 CRS: supportive care. Grade 2 CRS: tocilizumab (anti-IL-6 receptor antibody) 8 mg/kg IV. Grade 3-4 CRS: tocilizumab plus dexamethasone 10-20 mg IV every 6 hours.
Tocilizumab works within hours for CRS; if no response after 2 doses, add high-dose corticosteroids. Corticosteroids can impair CAR-T expansion and are therefore used after tocilizumab when possible. All patients receiving CAR-T must be monitored at a certified treatment center for at least 7 days post-infusion.
ICANS (Immune Effector Cell-Associated Neurotoxicity Syndrome). ICANS is a distinct neurological toxicity of CAR-T therapy occurring in approximately 20-60% of patients, often overlapping with or following CRS.9 Pathophysiology involves CAR-T cell trafficking into the CNS (central nervous system), endothelial activation, blood-brain barrier disruption, and cytokine-mediated neuronal injury. ICANS presents as encephalopathy (confusion, disorientation, attention deficit), aphasia, tremor, and in severe cases, cerebral edema, seizures, and coma. ICE (immune effector cell-associated encephalopathy) score, which tests orientation, naming, following commands, writing, and attention, grades encephalopathy from 0-10; an ICE score below 7 in adults or below 5 in children defines grade 2 or higher ICANS. Grade 1-2 ICANS: hold CAR-T (none to re-infuse anyway), supportive care, dexamethasone 10 mg IV twice daily; grade 3-4 ICANS: IV dexamethasone 20 mg every 6 hours; anti-epileptics (levetiracetam is preferred; avoid phenytoin due to sedation) for seizures; ICU-level care for cerebral edema. Unlike CRS, tocilizumab is not effective for ICANS (IL-6 blockade may actually worsen CNS toxicity by elevating free IL-6 that crosses the blood-brain barrier); corticosteroids are the primary treatment. ICANS is generally reversible in most cases but severe grade 4 ICANS with cerebral edema has a high mortality.
Neuroendocrine Tumor Pharmacology: Somatostatin Analogs. Neuroendocrine tumors (NETs) of the gastrointestinal tract and pancreas frequently overexpress somatostatin receptors (SSTR [somatostatin receptor] subtypes 1-5, particularly SSTR2 and SSTR5), which are the targets of somatostatin analog therapy.10 Octreotide and lanreotide are long-acting somatostatin analogs that suppress secretion of hormones from functional NETs (reducing carcinoid syndrome symptoms including flushing, diarrhea, and bronchoconstriction) and provide antiproliferative effects in well-differentiated NETs. Octreotide LAR (long-acting release) is administered as a monthly deep intramuscular injection; lanreotide depot is administered as a monthly deep subcutaneous injection. Both are metabolized primarily by the liver (not CYP [cytochrome P450]-dependent to a clinically significant extent) and can cause biliary sludge and gallstones with long-term use (requiring periodic abdominal ultrasound). Pasireotide is a newer somatostatin analog with broader receptor affinity (SSTR1, 2, 3, 5) and is approved for Cushing disease and acromegaly; its broader SSTR5 activity increases insulin secretion suppression, causing significantly more hyperglycemia than octreotide or lanreotide (glucose monitoring and management are intensified). For SSTR-positive progressive NETs, everolimus (mTOR [mechanistic target of rapamycin] inhibitor) and sunitinib (VEGFR [VEGF receptor]/PDGFR [platelet-derived growth factor receptor] TKI) provide additional antiproliferative options, and peptide receptor radionuclide therapy (PRRT) with lutetium-177 dotatate (Lutathera) targets SSTR-expressing tumor cells with a radiopharmaceutical.
All FDA-approved CAR-T products require REMS certification: only REMS-certified healthcare facilities may dispense and administer CAR-T products. Certification requires staff training in CRS and ICANS recognition, immediate access to tocilizumab, on-site ICU capability, and neurology consultation availability. Patients must be monitored at the treatment center for at least 7 days after infusion and must not drive or operate heavy machinery for at least 8 weeks post-infusion due to ICANS risk. Patients must carry a CAR-T patient card for at least 2 years post-infusion to alert emergency providers of this history, as late CRS and ICANS have been reported weeks after infusion. Corticosteroids must be available on-site before each infusion begins.
This final section consolidates the highest-yield clinical decision points from Module 04, with cross-references to the broader ACD2 (Anti-Cancer Drugs Part 2) chapter content, to prepare for T3/T4 (higher-order clinical vignette)-level scenarios involving ICI (immune checkpoint inhibitor) toxicity management, hormonal therapy drug interactions, and CAR-T (chimeric antigen receptor T-cell) therapy complication recognition.
irAE Recognition and Triage. The most clinically tested irAE scenarios involve: (1) immune colitis — new diarrhea of more than 4 extra stools per day in an ICI-treated patient requires stool culture, C. difficile testing, and initiation of prednisone 1 mg/kg/day while awaiting results; infliximab is the steroid-sparing agent of choice for grade 3-4 refractory colitis, not mycophenolate mofetil; (2) immune hepatitis — new transaminase elevation requires weekly LFT (liver function test) monitoring; grade 3 hepatitis (more than 5 times ULN) requires methylprednisolone 1-2 mg/kg/day and mycophenolate mofetil (not infliximab) if steroid-refractory; (3) immune pneumonitis — new ground-glass opacities on CT (computed tomography) in an ICI-treated patient require bronchoscopy to exclude infection and initiation of prednisone 1-2 mg/kg/day for grade 2 or higher; permanently discontinue ICI for grade 3-4.3 The most common error is insufficient steroid dosing (less than 1 mg/kg/day) or premature taper (less than 4 weeks), both causing irAE relapse. A second common error is giving infliximab for immune hepatitis, which is contraindicated due to its own hepatotoxicity.
Endocrine irAE Management Distinctions. Adrenal insufficiency from ICI-related hypophysitis or primary adrenal failure is a medical emergency if the patient presents in adrenal crisis (hypotension, vomiting, hyponatremia, hyperkalemia): give IV hydrocortisone 100 mg immediately, then 50-100 mg every 6-8 hours; do not wait for test results before treating suspected adrenal crisis.4 For non-urgent presentations, draw ACTH (adrenocorticotropic hormone) and cortisol before starting steroids to preserve diagnostic utility. Hypothyroidism from ICI is usually asymptomatic initially and discovered on routine TSH (thyroid-stimulating hormone) monitoring; treat with levothyroxine and continue ICI. Hyperthyroidism from ICI-induced thyroiditis is transient (thyroid hormone stored in colloid is released); treat symptomatically with beta-blockers; hyperthyroidism typically transitions to hypothyroidism within 4-8 weeks. All endocrine irAEs require lifelong hormone replacement even after ICI discontinuation because the gland damage is permanent.
CRS (Cytokine Release Syndrome) vs. ICANS (Immune Effector Cell-Associated Neurotoxicity Syndrome). CRS and ICANS both occur after CAR-T infusion but are mechanistically and therapeutically distinct. CRS: fever is the hallmark; hypotension and hypoxia define severity; elevated IL-6 (interleukin-6), ferritin, and CRP (C-reactive protein); treat with tocilizumab first, then add steroids. ICANS: neurological symptoms (confusion, aphasia, seizure) in the absence of fever in established cases; tocilizumab is ineffective and may worsen ICANS; treat exclusively with dexamethasone; levetiracetam for seizure prophylaxis.9 Both can co-occur; when both CRS and ICANS are present, treat the more severe condition first and initiate both tocilizumab and dexamethasone. If a patient develops fever plus confusion after CAR-T infusion, evaluate both simultaneously; do not assume confusion is infection without ruling out ICANS first.
Hormonal Therapy Drug Interaction Priorities. Four drug interactions from this module are highest-yield: (1) enzalutamide is a strong CYP3A4 (cytochrome P450 3A4) inducer — co-administration with warfarin, direct oral anticoagulants, docetaxel, and most other oncology agents dramatically reduces their plasma levels; always review the full medication list before starting enzalutamide and after any dose change;7 (2) tamoxifen and CYP2D6 (cytochrome P450 2D6) inhibitors — avoid paroxetine and fluoxetine; substitute venlafaxine or gabapentin for hot flashes; (3) abiraterone must be taken on an empty stomach (high-fat meal raises AUC 5-fold); abiraterone requires concurrent prednisone 5 mg twice daily to suppress mineralocorticoid accumulation; (4) GnRH agonists cause testosterone flare — always co-prescribe a short-course antiandrogen (bicalutamide 50 mg daily for 4 weeks) at GnRH agonist initiation in patients with high tumor burden or risk of obstructive symptoms.
ICI Contraindications and Special Populations. Active autoimmune disease requiring systemic immunosuppression is a relative contraindication to ICI therapy; rheumatoid arthritis, inflammatory bowel disease, psoriasis, and multiple sclerosis on stable maintenance therapy can receive ICI with careful monitoring and proactive irAE management, but solid organ transplant recipients face high risk of graft rejection from PD-1 (programmed death 1)/PD-L1 (programmed death ligand 1) blockade (renal allograft rejection rates of approximately 40% in case series). HIV (human immunodeficiency virus)-positive patients on antiretroviral therapy with undetectable viral load and CD4 (cluster of differentiation 4) count above 350 cells/microliter can receive ICI; viral loads and CD4 counts should be monitored. Patients requiring chronic corticosteroid therapy (prednisone more than 10 mg/day equivalent) have attenuated ICI response rates in retrospective data; steroid tapering to less than 10 mg/day before ICI initiation is recommended when clinically feasible. Live vaccines should not be administered during ICI therapy; inactivated vaccines are safe but immunogenicity may be reduced.12
Melanoma patient on nivolumab-ipilimumab with 8 stools/day and abdominal pain: grade 3 immune colitis; permanently discontinue ipilimumab; hold nivolumab; start IV methylprednisolone 2 mg/kg/day; if no improvement at day 3, add infliximab 5 mg/kg IV. Patient on pembrolizumab with TSH 0.05, free T4 elevated, heart rate 110: ICI-induced thyroiditis with hyperthyroidism; treat with beta-blocker; do not start methimazole yet (transient); continue pembrolizumab; recheck TSH in 4-8 weeks (expect to become hypothyroid). Metastatic prostate cancer patient starting leuprolide with vertebral bone metastases: MUST give bicalutamide 50 mg daily for 4 weeks before and concurrent with leuprolide to prevent testosterone flare causing spinal cord compression. Patient on abiraterone with blood pressure 158/96, serum potassium 3.1 mEq/L: mineralocorticoid excess due to CYP17A1 inhibition; confirm prednisone 5 mg twice daily is being taken; add amlodipine for hypertension; supplement potassium. ER+ breast cancer patient on tamoxifen requesting paroxetine for hot flashes: switch to venlafaxine or gabapentin; paroxetine inhibits CYP2D6 and reduces endoxifen levels. Post-CAR-T patient day 6 with confusion, aphasia, and ICE score of 4: grade 3 ICANS; start dexamethasone 20 mg every 6 hours; do NOT give tocilizumab (ineffective for ICANS, may worsen); start levetiracetam; arrange ICU monitoring.
Larkin J, Chiarion-Sileni V, Gonzalez R, et al. Five-year survival with combined nivolumab and ipilimumab in advanced melanoma. N Engl J Med. 2019;381(16):1535-1546.
doi:10.1056/NEJMoa1910836Herbst RS, Baas P, Kim DW, et al. Pembrolizumab versus docetaxel for previously treated, PD-L1-positive, advanced non-small-cell lung cancer (KEYNOTE-010): a randomised controlled trial. Lancet. 2016;387(10027):1540-1550.
doi:10.1016/S0140-6736(15)01281-7Haanen J, Obeid M, Spain L, et al. Management of toxicities from immunotherapy: ESMO clinical practice guideline for diagnosis, treatment and follow-up. Ann Oncol. 2022;33(12):1217-1238.
doi:10.1016/j.annonc.2022.10.001Delivanis DA, Gustafson MP, Bornschlegl S, et al. Pembrolizumab-induced thyroiditis: comprehensive clinical review and insights into underlying involved mechanisms. J Clin Endocrinol Metab. 2017;102(8):2770-2780.
doi:10.1210/jc.2017-00448Marabelle A, Fakih M, Lopez J, et al. Association of tumour mutational burden with outcomes in patients with advanced solid tumours treated with pembrolizumab: prospective biomarker analysis of the multicohort, open-label, phase 2 KEYNOTE-158 study. Lancet Oncol. 2020;21(10):1353-1365.
doi:10.1016/S1470-2045(20)30445-9Le DT, Durham JN, Smith KN, et al. Mismatch repair deficiency predicts response of solid tumors to PD-1 blockade. Science. 2017;357(6349):409-413.
doi:10.1126/science.aan6733Davis ID, Martin AJ, Stockler MR, et al. Enzalutamide with standard first-line therapy in metastatic prostate cancer. N Engl J Med. 2019;381(2):121-131.
doi:10.1056/NEJMoa1903835Davies C, Pan H, Godwin J, et al. Long-term effects of continuing adjuvant tamoxifen to 10 years versus stopping at 5 years after diagnosis of oestrogen receptor-positive breast cancer: ATLAS, a randomised trial. Lancet. 2013;381(9869):805-816.
doi:10.1016/S0140-6736(12)61963-1Maude SL, Laetsch TW, Buechner J, et al. Tisagenlecleucel in children and young adults with B-cell lymphoblastic leukemia. N Engl J Med. 2018;378(5):439-448.
doi:10.1056/NEJMoa1709866Strosberg J, El-Haddad G, Wolin E, et al. Phase 3 trial of 177Lu-dotatate for midgut neuroendocrine tumors. N Engl J Med. 2017;376(2):125-135.
doi:10.1056/NEJMoa1607427Antonia SJ, Villegas A, Daniel D, et al. Overall survival with durvalumab after chemoradiotherapy in stage III NSCLC. N Engl J Med. 2018;379(24):2342-2350.
doi:10.1056/NEJMoa1809697Neelapu SS, Locke FL, Bartlett NL, et al. Axicabtagene ciloleucel CAR T-cell therapy in refractory large B-cell lymphoma. N Engl J Med. 2017;377(26):2531-2544.
doi:10.1056/NEJMoa1707447Reck M, Rodriguez-Abreu D, Robinson AG, et al. Pembrolizumab versus chemotherapy for PD-L1-positive non-small-cell lung cancer. N Engl J Med. 2016;375(19):1823-1833.
doi:10.1056/NEJMoa1606774